437 research outputs found
Life Science on the International Space Station Using the Next Generation of Cargo Vehicles
With the retirement of the Space Shuttle and the transition of the International Space Station (ISS) from assembly to full laboratory capabilities, the opportunity to perform life science research in space has increased dramatically, while the operational considerations associated with transportation of the experiments has changed dramatically. US researchers have allocations on the European Automated Transfer Vehicle (ATV) and Japanese H-II Transfer Vehicle (HTV). In addition, the International Space Station (ISS) Cargo Resupply Services (CRS) contract will provide consumables and payloads to and from the ISS via the unmanned SpaceX (offers launch and return capabilities) and Orbital (offers only launch capabilities) resupply vehicles. Early requirements drove the capabilities of the vehicle providers; however, many other engineering considerations affect the actual design and operations plans. To better enable the use of the International Space Station as a National Laboratory, ground and on-orbit facility development can augment the vehicle capabilities to better support needs for cell biology, animal research, and conditioned sample return. NASA Life scientists with experience launching research on the space shuttle can find the trades between the capabilities of the many different vehicles to be confusing. In this presentation we will summarize vehicle and associated ground processing capabilities as well as key concepts of operations for different types of life sciences research being launched in the cargo vehicles. We will provide the latest status of vehicle capabilities and support hardware and facilities development being made to enable the broadest implementation of life sciences research on the ISS
Patients with aortic stenosis exhibit early improved endothelial function following transcatheter aortic valve replacement: The eFAST study
BACKGROUND: Patients with severe aortic stenosis (AS) exhibit systemic endothelial dysfunction, which can be associated with myocardial ischaemia in absence of obstructive coronary disease. Transcatheter aortic valve replacement (TAVR) is used to treat severe AS in patients with high or prohibitive surgical risk. However, it remains unknown whether endothelial function recovers post-TAVR. We therefore sought to assess the early and late changes in flow-mediated dilation (FMD), a measure of endothelial function, following TAVR. METHODS: Patients undergoing TAVR for severe AS had ultrasound assessment of brachial endothelial-independent and -dependent FMD. Measurements were performed pre-TAVR, at early follow-up (<48 h post-TAVR) and late follow-up (4-6 weeks post-TAVR). RESULTS: 27 patients (mean age 82.0 ± 7.0; 33.3% female) were recruited; 37.0% had diabetes mellitus and 59.3% had hypertension. Brachial artery FMD increased from 4.2 ± 1.6% (pre-TAVR) to 9.7 ± 3.5% at early follow-up (p < 0.0001). At late follow-up, improvement compared with early follow-up was sustained (8.7 ± 1.9%, p = 0.27). Resting brachial arterial flow velocities decreased significantly at late follow-up (11.24 ± 5.16 vs. 7.73 ± 2.79 cm/s, p = 0.003). Concordantly, at late follow-up, there was decrease in resting wall shear stress (WSS; 14.8 ± 7.8 vs. 10.6 ± 4.8dyne/cm2, p = 0.01), peak WSS (73.1 ± 34.1 vs. 58.8 ± 27.8dyne/cm2, p = 0.03) and cumulative WSS (3543 ± 1852 vs. 2504 ± 1089dyne·s/cm2, p = 0.002). Additionally, a favourable inverse correlation between cumulative WSS and FMD was restored at late follow-up (r = -0.21 vs. r = 0.49). CONCLUSION: Endothelial function in patients with AS improves early post-TAVR and this improvement is sustained. This likely occurs as a result of improved arterial haemodynamics, leading to lower localised WSS and release of vasoactive mediators that may also alleviate myocardial ischaemia
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy
n/
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
The aim of the present study was to define the activity and tolerability of a triplet regimen including oxaliplatin 130âmgâmâ2 (2âh i.v. infusion) and raltitrexed 3.0âmgâmâ2 (15âmin i.v. infusion) given on day 1, followed by levo-folinic acid 250âmgâmâ2 (2âhâi.v. infusion) and 5-fluorouracil 1050âmgâmâ2âi.v. bolus on day 2, every 2 weeks, in pretreated colorectal cancer patients. From April 1999 to December 2000, 50 patients were enrolled: 26 were males and 24 females, their median age was 63 (range, 43â79) years; ECOG performance status was 0 in 26 patients, â©Ÿ1 in 24 patients; 26 patients had received previous adjuvant chemotherapy, 40 patients had been exposed to one or two lines of palliative chemotherapy (including irinotecan in 31 cases); 18 patients were considered chemo-refractory. A total of 288 cycles were administered, with a median number of 6 (range 1â12) courses per patient. A complete response was obtained in three patients, and a partial response in nine patients, giving a major response rate of 24% (95% confidence interval, 13â38%), while 15 further patients showed a stable disease, for an overall control of tumour growth in 60% of patients. Three complete responses and three partial responses were obtained in patients pretreated with irinotecan (response rate, 19%); among refractory patients, three achieved partial responses (response rate, 13%). After a median follow-up of 18 (range, 10â30) months, 40 patients showed a progression of disease: the growth modulation index ranged between 0.2 and 2.5: it was â©Ÿ1.33 (showing a significant delay of tumour growth) in 16 (40%) patients. Actuarial median progression-free survival time was 7.6 months, and median survival time was 13.6 months: estimated probability of survival was 55% at 1 year. Main severe toxicity was neutropenia: World Health Organisation grade 4 affected 32% of patients; non-haematological toxicity was mild: World Health Organisation grade 3 diarrhoea was complained of by 8%, and grade 3 stomatitis by 4% of patients; neurotoxicity (according to LĂ©vi scale) was scored as grade 3 in 8% of patients. In conclusion, this regimen was manageable and active as salvage treatment of advanced colorectal cancer patients; it showed incomplete cross-resistance with irinotecan-based treatments, and proved to delay the progression of disease in a relevant proportion of treated patients
Recommended from our members
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin versus Toxin-NaĂŻve Subjects with Cervical Dystonia
Background: To determine whether botulinum toxin treatment history affected the outcomes of a study comparing the safety and efficacy of incobotulinumtoxinA with placebo in subjects with cervical dystonia (CD). Methods: This was a prospective, doubleâblind, randomized, placeboâcontrolled, multicenter trial in botulinum toxinâtreated or toxinânaĂŻve CD subjects. Subjects received a fixed dose of either 120 U or 240 U of incobotulinumtoxinA or placebo. The primary outcome measure was change from baseline to Week 4 in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score. Treatmentâemergent adverse events (TEAEs) were also evaluated. This report represents a subgroup analysis of botulinum toxinâtreated or toxinânaĂŻve subjects. Results: Participants (Nâ=â233; 38.6% toxinânaĂŻve) had a mean age of 52.8 years. IncobotulinumtoxinA significantly improved TWSTRS total scores from baseline to Week 4 in both dose groups versus placebo, and the improvement persisted through the end of the study (â€20 weeks). Both the previously toxinâtreated and toxinânaĂŻve subjects demonstrated significant improvements in TWSTRS total scores at Week 4 compared to baseline. The most frequent TEAEs in the incobotulinumtoxinA groups were dysphagia, neck pain, and muscular weakness, which were generally mild. TEAEs were more common in the 240 U group and toxinânaĂŻve subjects. Discussion: Overall, incobotulinumtoxinA was safe and effective in CD, regardless of toxin therapy history. A lower starting dose may be better tolerated among toxinânaĂŻve subjects without sacrificing efficacy
Building better Sex Robots: Lessons from Feminist Pornography
How should we react to the development of sexbot technology? Taking their cue from anti-porn feminism, several academic critics lament the development of sexbot technology, arguing that it objectifies and subordinates women, is likely to promote misogynistic attitudes toward sex, and may need to be banned or restricted. In this chapter I argue for an alternative response. Taking my cue from the sex positive âfeminist pornâ movement, I argue that the best response to the development of âbadâ sexbots is to make better ones. This will require changes to the content, process and context of sexbot development. Doing so will acknowledge the valuable role that technology can play in human sexuality, and allow us to challenge gendered norms and assumptions about male and female sexual desire. This will not be a panacea to the social problems that could arise from sexbot development, but it offers a more realistic and hopeful vision for the future of this technology in a pluralistic and progressive society
Neuronal survival induced by neurotrophins requires calmodulin
It has been reported that phosphoinositide 3-kinase (PI 3-kinase) and its downstream target, protein kinase B (PKB), play a central role in the signaling of cell survival triggered by neurotrophins (NTs). In this report, we have analyzed the involvement of Ca2+ and calmodulin (CaM) in the activation of the PKB induced by NTs. We have found that reduction of intracellular Ca2+ concentration or functional blockade of CaM abolished NGF-induced activation of PKB in PC12 cells. Similar results were obtained in cultures of chicken spinal cord motoneurons treated with brain-derived neurotrophic factor (BDNF). Moreover, CaM inhibition prevented the cell survival triggered by NGF or BDNF. This effect was counteracted by the transient expression of constitutive active forms of the PKB, indicating that CaM regulates NT-induced cell survival through the activation of the PKB. We have investigated the mechanisms whereby CaM regulates the activation of the PKB, and we have found that CaM was necessary for the proper generation and/or accumulation of the products of the PI 3-kinase in intact cells
- âŠ